In addition to the presentation of the results of the VALOR-HCM study which compared mavacamten to septal reduction techniques, covered here in its own HCMBeat blog entry, ACC 2022 featured two other presentations about the new class of drugs known as myosin inhibitors, such as Bristol Myers Squibb’s mavacamten and Cytokinetics’ aficamten.
The following guidelines have been developed by HCM specialists at the following hospitals: Brigham and Women’s Hospital in Boston, Careggi University in Florence, Italy, Stanford University, the University of Michigan and the University of Pennsylvania.
At the bottom of this page you will find the document as a pdf file which should allow you access to the links contained in the document.
HCM Beat 